Details
Category: Volume 07 Issue 06 June 2019
Hits: 1258

Title: Incidence of HER2 overexpression in oral squamous cell carcinoma- A prospective study in a tertiary care centre in eastern India

Authors: Sunil Agrawala, Aalapti Singh, Venkata Rao Epari, Twinkle Rout, Debiprasad Mohanty, Manoj Sahoo, Surendra Nath Swain, Sourav Mishra

 DOI: https://dx.doi.org/10.18535/jmscr/v7i6.112

Abstract

Aim: HER 2/Neu, a member of EGFR family, is over expressed in some tumour. There is a large variation in the percentage of overexpression of HER 2 /Neu in western vs India, where chewing tobacoo is a common practice. The purpose of this study was to determine the tissue expressing of HER 2/neu in patients with Head & Neck oral Squamous Cell Carcinoma (HNSCC) and any co-relation with its epidemiological parameter.

Methods: IHC was used to access tissue expression of HER 2/neu in 74 patients with HNSCC during period of 2016 to 2018. All patients were of oral cancer. Both biopsy and resected specimen taken for study.

Results:  Out of 74 patients 21 patients (28.4%) showed strong HER 2/Neu positivity. Those participated in this study were 63(85%) male & 11(14.9%) were female.

Socioeconomic status -31 patients (41.9%) never gone to school , 61 patients (82.4%) uses tobacco .All the 74 patients (100%) presented with ulcer inside mouth (oral cavity) lesion with 13(17.5%) patients having co-morbidities.

Conclusion:  In our cases HER 2/Neu overexpression seen in 28.4% of cases. This finding suggest that further sub-analysis with reference to HER 2 as a prognostic marker & its therapeutic implication is further required.

Keywords; HER 2/Neu, Head and neck cancer. 

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018 Nov 1 [cited 2019 Feb 13];68(6):394–424. Available from: http://doi.wiley.com/10.3322/caac.21492
  2. Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma [Internet]. Vol. 21, Clinical Cancer Research. 2015 [cited 2019 Feb 11]. p. 526–33. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315724/pdf/nihms-644451.pdf
  3. Union for International Cancer Control. LOCALLY ADVANCED SQUAMOUS CARCINOMA OF THE HEAD AND NECK [Internet]. 2014 Review of Cancer Medicines on the WHO List of Essential Medicines. 2014 [cited 2019 Feb 13]. Available from: https://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf
  4. Sharma M, Madan M, Manjari M, Bhasin TS, Jain S, Garg S. Prevalence of Head and Neck Squamous Cell Carcinoma ( HNSCC ) in our population : The clinic-pathological and morphological description of 198 cases . Patients and Methods : Int J Adv Res [Internet]. 2015 [cited 2019 Feb 11];3(1):827–33. Available from: http://www.journalijar.com
  5. Yeole BB, Ramanakumar A V, Sankaranarayanan R. Survival from oral cancer in Mumbai (Bombay), India. Cancer Causes Control [Internet]. 2003 Dec [cited 2019 Feb 14];14(10):945–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14750533
  6. Güneri P, Çankaya H, Yavuzer A, Güneri EA, Erişen L, Özkul D, et al. Primary oral cancer in a Turkish population sample: Association with sociodemographic features, smoking, alcohol, diet and dentition. Oral Oncol [Internet]. 2005 Nov 1 [cited 2019 Feb 14];41(10):1005–12. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1368837505001594?via%3Dihub
  7. de Lyra RR, de Macedo-Soares TDL va. A. Strategic alliance governance forms. Corp Ownersh Control [Internet]. 2011 Jan 1 [cited 2019 Feb 11];8(4 D):334–44. Available from: http://doi.wiley.com/10.3322/caac.21166
  8. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. In: Annals of Oncology [Internet]. 2010 [cited 2019 Feb 7]. p. vii252-vii261. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20943624
  9. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (80- ) [Internet]. 1985 Dec 6 [cited 2019 Feb 12];230(4730):1132–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2999974
  10. Anderson NG, Ahmad T. ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Front Biosci [Internet]. 2002 Sep 1 [cited 2019 Feb 7];7:d1926-40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12161338
  11. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network [Internet]. Vol. 2, Nature Reviews Molecular Cell Biology. 2001 [cited 2019 Feb 7]. p. 127–37. Available from: http://www.nature.com/articles/35052073
  12. Lenferink AEGG, Pinkas-Kramarski R, Van De Poll MLMM, Van Vugt MJHH, Klapper LN, Tzahar E, et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J [Internet]. 1998 Jun 15 [cited 2019 Feb 11];17(12):3385–97. Available from: http://emboj.embopress.org/content/embojnl/17/12/3385.full.pdf
  13. Lenferink AEG, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27Kip1and cyclin D1 through multiple signaling pathways. Cancer Res [Internet]. 2001 Sep 1 [cited 2019 Feb 11];61(17):6583–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11522658
  14. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol [Internet]. 1996 Oct [cited 2019 Feb 11];16(10):5276–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8816440
  15. Kibirova A, Hall SJ, Salken MA. HER2-Positive Breast Cancer: Current Management | MDedge Hematology and Oncology [Internet]. Hospital Physician Hematology-Oncology Board Review Manual; 2018 [cited 2019 Feb 14]. p. 34–48. Available from: https://www.mdedge.com/hematology-oncology/article/165824/breast-cancer/her2-positive-breast-cancer-current-management
  16. Manjari M, Popli R, Paul S, Gupta VP, Kaholon SK. Prevalence of oral cavity, pharynx, larynx and nasal cavity malignancies in Amritsar, Punjab. Indian J Otolaryngol Head Neck Surg [Internet]. 1996 [cited 2019 Feb 14];48(3):191–5. Available from: https://link.springer.com/article/10.1007/BF03048602
  17. Ravi M, Mamata S, Kishore GR, Manish S, Anil K K, Mehrotra R, et al. Trends of prevalence and pathological spectrum of head and neck cancers in North India. Indian J Cancer [Internet]. 2005 [cited 2019 Feb 14];42(2):89–93. Available from: http://www.indianjcancer.com
  18. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. Arch Pathol Lab Med [Internet]. 2014 Feb [cited 2019 Feb 11];138(2):241–56. Available from: http://www.archivesofpathology.org/doi/abs/10.5858/arpa.2013-0953-SA
  19. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: A practical approach [Internet]. Vol. 25, Modern Pathology. 2012 [cited 2019 Feb 11]. p. 637–50. Available from: http://www.nature.com/articles/modpathol2011198
  20. Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck [Internet]. 2007 Jul [cited 2019 Feb 11];29(7):655–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17315173
  21. Sardari Y, Pardis S, Tadbir AA, Ashraf MJ, Fattahi MJ, Ebrahimi H, et al. HER2/neu Expression in Head and Neck Squamous Cell Carcinoma Patients is not Significantly Elevated. Asian Pacific J Cancer Prev [Internet]. 2012 [cited 2019 Feb 11];13(6):2891–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22938479
  22. Angiero F, Sordo R Del, Dessy E, Rossi E, Berenzi A, Stefani M, et al. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: Does over-expression exist? And what is its correlation with traditional diagnostic parameters? J Oral Pathol Med [Internet]. 2008 Mar 29 [cited 2019 Feb 11];37(3):145–50. Available from: http://doi.wiley.com/10.1111/j.1600-0714.2007.00603.x
  23. Wilkman TSE, Hietanen JHP, Malmström MJ, Konttinen YT. Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg [Internet]. 1998 Jun [cited 2019 Feb 14];27(3):209–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9662015
  24. Conway DI, Petticrew M, Marlborough H, Berthiller J, Hashibe M, Macpherson LMD. Socioeconomic inequalities and oral cancer risk: A systematic review and meta-analysis of case-control studies. Int J Cancer [Internet]. 2008 Jun 15 [cited 2019 Feb 11];122(12):2811–9. Available from: http://doi.wiley.com/10.1002/ijc.23430.

Corresponding Author

Dr Surendra Nath Swain

Associate Professor, Department of Medicine, IMS and SUM Hospital, Siksha O Anusandhan Deemed to be University